Lipid metabolism

Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023  

Retrieved on: 
Monday, November 6, 2023
Adiponectin, Arm, University, American Association for the Study of Liver Diseases, Hepatology, Diabetes, II, Liver, C-reactive protein, CAP, Genotype, Lipid metabolism, Fibrosis, Metabolic syndrome, PNPLA3, Inflammation, Type 2 diabetes, HOMA-IR, Euronext Paris, Scan (company), Steatosis, NASH, Risk, Insulin, T2D, Abstract, Histology, Serum, MM, Insulin resistance, Adipose tissue, Patient, Fatty liver disease, Metabolism, Glucose, Medical device, Medical imaging, Pharmaceutical industry

The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.

Key Points: 
  • The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.
  • Two additional scientific abstracts from the NATIVE Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH have been selected  for presentation.
  • The two abstracts show:
    the correlation between the increase of adiponectin under lanifibranor and the improvement of histological and serum markers of NASH severity both in terms of activity and fibrosis.
  • the improvement of liver histology and markers of cardiometabolic health in patients with NASH treated with lanifibranor, independent of PNPLA3 genotype.

Shineco Opens Healthy Food Restaurant with Focus on Advanced Nutrition

Retrieved on: 
Monday, October 30, 2023
Taste, Dartmouth College, Health, Food, SISI, Lipid metabolism, Research, Metabolism, Trust, Peking Union Medical College, Hormone, Safety, Insulin resistance, Hygiene, Glucose, Insulin, Dietary supplement

BEIJING, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today the grand opening of its first carry-out restaurant which will sell Shineco’s new healthy and nutritious food brand, ‘Meida Nutritionary Restaurant”. Shineco’s first carry-out restaurant is located on Baihuazhou Road, Cangshan, Fuzhou City, China. Shineco’s official entry into the healthy food market represents a further evolution of the medical and health company’s operations, which has been long engaged in the field of life sciences.

Key Points: 
  • BEIJING, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today the grand opening of its first carry-out restaurant which will sell Shineco’s new healthy and nutritious food brand, ‘Meida Nutritionary Restaurant”.
  • Dr. Fengming Liu, the leader of Shineco’s Healthy Food Project, has a doctorate from Peking Union Medical College and is a postdoctoral fellow at Dartmouth College.
  • Shineco decided to enter the healthy food market in order to introduce life science concepts that encompass nutrition, health, and functionality while maintaining convenience, speed and taste.
  • The healthy carry-out meals launched by Shineco incorporates life science research that has given rise to using food to regulate insulin resistance and improve glucose and lipid metabolism.

NImmune Biopharma Announces Positive Results of Omilancor in Ulcerative Colitis and Crohn’s disease at the American College of Gastroenterology 2023 Annual Scientific Meeting

Retrieved on: 
Monday, October 23, 2023
Research, Clinical Trials, Biotechnology, Health, University, Pharmaceutical, General Health, Science, Education, Patient, American College, UC, The American Journal of Gastroenterology, LANCL2, ACG, Lipid metabolism, Safety, American College of Gastroenterology, Ulcerative colitis, Abstract, New Drug Application, Biomarker, NDA, Neutrophil, American Journal, Gene expression, CD, Pharmaceutical industry, Medical device, Medical imaging

Durable remission was induced in 38.5% of patients in the omilancor group versus 21.4% of patients given placebo (Δ=17.1, P = 0.05).

Key Points: 
  • Durable remission was induced in 38.5% of patients in the omilancor group versus 21.4% of patients given placebo (Δ=17.1, P = 0.05).
  • Title: Efficacy and Safety of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients with Crohn’s Disease.
  • Title: Transcriptional Analysis of Colonic Biopsies from Patients with Ulcerative Colitis Treated with Omilancor.
  • Additionally, the peer-reviewed accepted abstracts will be published verbatim in a special supplement to the October 2023 issue of The American Journal of Gastroenterology.

Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction

Retrieved on: 
Tuesday, October 10, 2023
Cardiovascular disease, Syndrome, TSX, Cannabidiol, BNP, Hypertension, Obesity, Tibia, Death, Inflammation, Development, Risk, Adipose tissue, Human, Diabetes, VAT, Patient, SAT, Therapy, Heart failure, Lipid metabolism, CRDL, Fibrosis, Skin, Research, Pharmaceutical industry, Heart failure with preserved ejection fraction

Toronto, Ontario--(Newsfile Corp. - October 10, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces positive study results from one of its international collaborating research centers demonstrating that subcutaneously administered cannabidiol, the active pharmaceutical ingredient in Cardiol's novel CRD-38 subcutaneous ("SUBQ") formulation, slowed increases in body weight and heart weight, and prevented increases in key cardiac inflammatory and remodelling markers in a model of heart failure with preserved ejection fraction ("HFpEF").

Key Points: 
  • The study was presented by researchers from Tecnológico de Monterrey, Mexico ("TecSalud") at the Heart Failure Society of America Annual Scientific Meeting 2023 ("HFSA2023").
  • TecSalud is one of the Company's international collaborating research centers working towards the common goal of developing products to advance the treatment of heart diseases.
  • The results presented at the HFSA over the weekend demonstrated multiple cardioprotective effects of SUBQ administered cannabidiol and provide additional evidence in support of the development of CRD-38, our novel SUBQ formulation of cannabidiol intended for the treatment of heart failure.
  • The poster entitled "Cannabidiol As A Potential Treatment For Heart Failure With Preserved Ejection Fraction" was presented on October 7th within the "ePoster Viewing Session III" of HFSA2023.

Cytoki Pharma Presents Preclinical Data Demonstrating Weight Reduction and Improved Glucose Control with Lipidated IL-22 at ObesityWeek 2023

Retrieved on: 
Monday, October 16, 2023
DIO, Pharmacokinetics, Obesity, Biology, Weight loss, Liver, Diabetes, DSM-IV codes, Safety, Administration, Human, Anpartsselskab, SC, Fasting, Lipid metabolism, Mouse, Phase 1, Glycated hemoglobin, Quality of life, Pharmaceutical industry

COPENHAGEN, Denmark, Oct. 16, 2023 /PRNewswire/ -- Cytoki Pharma, ApS (Cytoki), a clinical-stage biotechnology company pioneering a new class of medicines that harness IL-22 biology to drive improved outcomes for metabolic disease, today presented preclinical data demonstrating the potential of lipidated IL-22 to induce weight loss and positively impact a range of cardiometabolic risk factors at ObesityWeek 2023, held October 14-17 in Dallas.

Key Points: 
  • IL-22 is an atypical, non-immunomodulatory cytokine, which selectively targets epithelial tissues, including those that play important roles in metabolic processes, such as the gut and liver.
  • Cytoki's lipidated IL-22 analogues leverage this innate biology and offer first-in-class potential to address a range of metabolic diseases, including obesity and type 2 diabetes.
  • Subsequent studies in diabetic db/db mice indicate that treatment with lipidated IL-22 normalized blood glucose levels and reduced HbA1c levels independent of food intake, accompanied by dose-dependent insulin sensitization.
  • The presentation details are as follows:
    Location: Kay Bailey Hutchinson Convention Center, Room D174

Metabolon Launches New Liver Fibrosis and Kidney Function Discovery Panels to Reveal Disease Mechanisms and Facilitate Research

Retrieved on: 
Thursday, October 12, 2023
Medicine, Biomarker, Metabolomics, Liver, Death, Patient, Chronic liver disease, Chronic kidney disease, Lipid metabolism, Cirrhosis, Drug discovery, Kidney disease, Research, Dietary supplement, Metabolon

MORRISVILLE, N.C., Oct. 12, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announces the launch of its new Liver Fibrosis and Kidney Function Discovery Panels.

Key Points: 
  • As part of the Metabolon Discover portfolio of metabolomics services, Metabolon's new Liver Fibrosis and Kidney Function Discovery Panels assess multiple metabolites across diverse biological pathways associated with liver fibrosis and kidney disease, providing a greater understanding of these conditions.
  • Metabolon's Kidney Function Discovery Panel analyzes 84 metabolites associated with biochemical processes affecting kidney function to help researchers differentiate the diverse spectrum of kidney disease.
  • "Our new Liver Fibrosis and Kidney Function Discovery Panels seek to reveal fundamental metabolic changes, thereby facilitating our understanding of the underlying mechanisms of these diseases," said Rangaprasad (Ranga) Sarangarajan, Ph.D., Chief Scientific Officer at Metabolon.
  • To learn more about how Metabolon can help you gain functional insights into liver and kidney disease, please visit our Liver Fibrosis Discovery Panel and Kidney Function Discovery Panel pages.

Metabolon Launches New Liver Fibrosis and Kidney Function Discovery Panels to Reveal Disease Mechanisms and Facilitate Research

Retrieved on: 
Thursday, October 12, 2023
Medicine, Biomarker, Metabolomics, Liver, Death, Patient, Chronic liver disease, Chronic kidney disease, Lipid metabolism, Cirrhosis, Drug discovery, Kidney disease, Research, Dietary supplement, Metabolon

MORRISVILLE, N.C., Oct. 12, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announces the launch of its new Liver Fibrosis and Kidney Function Discovery Panels.

Key Points: 
  • As part of the Metabolon Discover portfolio of metabolomics services, Metabolon's new Liver Fibrosis and Kidney Function Discovery Panels assess multiple metabolites across diverse biological pathways associated with liver fibrosis and kidney disease, providing a greater understanding of these conditions.
  • Metabolon's Kidney Function Discovery Panel analyzes 84 metabolites associated with biochemical processes affecting kidney function to help researchers differentiate the diverse spectrum of kidney disease.
  • "Our new Liver Fibrosis and Kidney Function Discovery Panels seek to reveal fundamental metabolic changes, thereby facilitating our understanding of the underlying mechanisms of these diseases," said Rangaprasad (Ranga) Sarangarajan, Ph.D., Chief Scientific Officer at Metabolon.
  • To learn more about how Metabolon can help you gain functional insights into liver and kidney disease, please visit our Liver Fibrosis Discovery Panel and Kidney Function Discovery Panel pages.

NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation

Retrieved on: 
Thursday, September 21, 2023
Cognition, Oxysterol, University, Cardiovascular disease, Pathology, Pharmacokinetics, NAMS, Brain, Apolipoprotein, Biomarker, Cerebrospinal fluid, Disability, Reno 1868 FC, Plasma, Patient, CETP, Risk, Lipid metabolism, CSF, AD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Food, FESC, Neuroinflammation, Disease, Pharmaceutical industry, Medical imaging, Apolipoprotein E

NAARDEN, The Netherlands and MIAMI, Sept. 21, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced initial data from its Phase 2a clinical trial evaluating obicetrapib in patients with early Alzheimer’s disease (“AD”) and at least one copy of the apolipoprotein E4 mutation (“ApoE4”).

Key Points: 
  • This Phase 2a trial was designed to explore the effects of obicetrapib on lipid metabolism in the brains of early AD patients who are ApoE4 carriers.
  • As such, NewAmsterdam believes reductions of 24- and 27-hydroxycholesterol in the CSF may indicate improved cholesterol metabolism in the brain and may lead to improved cognitive function.
  • NewAmsterdam observed reductions in the levels of 24- and 27-hydroxycholestrol of 11% and 12%, respectively, in the CSF.
  • In addition, an increase of 8% in the Aβ42/40 ratio in patient’s plasma was observed and pTau181 levels were observed to be stable.

Elevate Your Fitness Journey with MitoSculpt by Nutrishop

Retrieved on: 
Wednesday, September 6, 2023
Exercise, Heart, Human, Panax notoginseng, History, Skeletal muscle, Lipid metabolism, Health, McLendon, Safety, Dietary supplement, Coleus

HENDERSON, Nev., Sept. 6, 2023 /PRNewswire/ -- Nutrishop® is proud to announce the launch of MitoSculpt™ by Illicit Labs®. This revolutionary metabolic formula was meticulously crafted with cutting-edge ingredients to support your fitness journey. MitoSculpt is stimulant-free, which makes it a great choice for those looking to manage their weight without the effects of high stimulants. This innovative product is now available exclusively at Nutrishop locations nationwide and online at NutrishopUSA.com.

Key Points: 
  • This revolutionary metabolic formula was meticulously crafted with cutting-edge ingredients to support your fitness journey.
  • "For those who prefer stimulants, MitoSculpt stacks really well with stimulant-based thermogenic supplements for an even greater effect when it comes to supporting your fitness journey," said McLendon.
  • As always, Nutrishop recommends speaking with your health care provider before embarking on any fitness journey to ensure health and safety first.
  • MitoSculpt is now available exclusively at Nutrishop locations across the United States and at NutrishopUSA.com .

LATEST EFSA Approval: Choline Acknowledged for the first time as Essential Nutrient for Normal Liver Function of the Foetus and Exclusively Breastfed Infants1

Retrieved on: 
Wednesday, August 30, 2023
Health, Consumer, Fitness & Nutrition, Baby, Maternity, General Health, Pharmaceutical, Biotechnology, Folate, Neural tube, Myopathy, Human, Pregnancy, Life, DHA, Prenatal care, Liver, Nutrient, Woman, HEALTH, Risk, De novo, Mother, EPA, De novo synthesis, Pulse, Fetus, EFSA, Lipid metabolism, Lactation, Cell division, Choline, Human body, P&G, Dietary supplement, EU

Choline is involved in the structure of cell membranes, cell signaling, neurotransmitter synthesis and contributes as phosphatidylcholine to a normal lipid metabolism and transport from the liver to extrahepatic tissues.

Key Points: 
  • Choline is involved in the structure of cell membranes, cell signaling, neurotransmitter synthesis and contributes as phosphatidylcholine to a normal lipid metabolism and transport from the liver to extrahepatic tissues.
  • Always on the Pulse of Science, Femibion® identified Choline as the next essential nutrient that could be crucial from the first moment of life in prenatal care.
  • That’s why today our Femibion portfolio contains Choline with Femibion® Phase 1 (early pregnancy), Femibion® Phase 2 (pregnancy) and Femibion® Phase 3 (breastfeeding).
  • Low maternal folate level is one of the risk factors in the development of neural tube defects in the developing foetus.